The National Agency for Food and Drug Administration and Control, NAFDAC on Sunday gave clarification about the original AstraZeneca COVID-19 vaccine, identifying its trade name as Covishield™.
This was disclosed in a statement titled: ‘Covishield™ vaccine is AstraZeneca/Oxford University Vaccine’ by Prof. Moji Christianah Adeyeye, Director General of NAFDAC.
She said ChAdOx1 recombinant adenoviral vector vaccine, used for prevention of COVID-19 disease was originally developed by AstraZeneca and Oxford University (AZOU).
She however noted that both COVISHIELD™ manufactured by Serum Institute of India Pvt Ltd and COVID-19 Vaccine AstraZeneca manufactured by AstraZeneca are the same vaccine – ChAdOx1 nCoV- 19 Corona Virus Vaccines (Recombinant).
She further stated that the Serum Institute of India PVT Ltd (SIIPL) was licensed by AZOU to manufacture this vaccine at commercial sale which led to the trade name COVISHIELD™
Providing more information about how the trade name came to be, the statement reads in part that “SIIPL is the largest vaccine manufacturer in the world and the company got the license by signing manufacturing agreement with AstraZeneca (AZ)/Oxford University to manufacture this vaccine. SIIPL gave the vaccine the trade name COVISHIELD™.”
Providing more information, it states that “COVISHIELDTM is the result of a cooperation and a technology transfer from AstraZeneca – University of Oxford to SIIPL.”
“Serum Institute of India Pvt. Ltd. is now the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization, Geneva and are being used in around 170 countries across the globe in their national immunization programs, saving millions of lives throughout the world.
Adeyeye revealed that COVISHIELDTM was granted Emergency Use Listing (EUL) by the World Health Organisation on 15th February, 2021 and it is one of the listed vaccines under the COVAX Facility.